So-Young Research and Development Expenses 2019-2024 | SY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

So-Young research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

So-Young Research and Development Expenses 2019-2024 | SY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

So-Young research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$91.4B
Cencora (COR)	$47.5B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$21.4B
ICON (ICLR)	$16.1B
Viatris (VTRS)	$15.6B
Avantor (AVTR)	$13.4B
Revvity (RVTY)	$13.4B
CochLear (CHEOY)	$12.8B
BioMerieux (BMXMF)	$12.7B
Solventum (SOLV)	$11.6B
Medpace Holdings (MEDP)	$9.8B
Doximity (DOCS)	$9.6B
Charles River Laboratories (CRL)	$9.5B
HealthEquity (HQY)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Sotera Health (SHC)	$3.9B
Organon (OGN)	$3.8B
BrightSpring Health Services (BTSG)	$3.2B
Surgery Partners (SGRY)	$2.9B
PACS (PACS)	$2.6B
Concentras Parent (CON)	$2.6B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.1B
Alignment Healthcare (ALHC)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
GoodRx Holdings (GDRX)	$1.6B